# US 2026/0098867 A1 · Metal nanoparticle, and plasmonic biosensor comprising the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0098867 A1
- Document ID: US20260098867A1
- Status: Published application
- Kind: A1
- Application number: 19/309,845
- Filed: 2025-08-26
- Published: 2026-04-09
- Earliest claimed: 2024-08-27
- Assignees: Korea University Research and Business Foundation
- Applicants: Korea University Research and Business Foundation
- Inventors: Sang Jun SIM; Seung Jong BAEK
- Web page: https://patentgrep.com/patent/US20260098867A1

## CPC

- G01N 33/6869: {Interleukin}
- G01N 21/554: {detecting the surface plasmon resonance of nanostructured metals, e.g. localised surface plasmon resonance}
- G01N 21/658: {enhancement Raman, e.g. surface plasmons}
- G01N 33/54346: {Nanoparticles}
- G01N 33/573: for enzymes or isoenzymes
- G01N 2333/5415: Leukaemia inhibitory factor [LIF]
- G01N 2333/91142: Pentosyltransferases (2.4.2)
- G01N 2800/26: Infectious diseases, e.g. generalised sepsis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to metal nanoparticles and a plasmonic biosensor including the same. According to the present invention, it is possible to provide novel metal nanoparticles having significantly improved sensitivity to light, and further, it is possible to provide a plasmonic biosensor capable of detecting a trace amount of a biomarker present in a biological sample with high precision through the metal nanoparticles. In addition, the plasmonic biosensor is capable of detecting a sepsis biomarker with high sensitivity and specificity, and thus may be usefully used in various clinical applications such as sepsis diagnosis, identification of the type of organ dysfunction, prediction of sepsis severity, and post-treatment.

## Claims

### Claim 1

A metal nanoparticle having a truncated octahedral structure composed of six (100) facets and eight (111) facets, wherein edges between four different adjacent (100) facets positioned with respect to any one of the (100) facets are truncated to form quadrangular connecting facets, wherein a concave channel is formed in each of the connecting facets.

### Claim 2 (depends on 1)

The metal nanoparticle of claim 1, wherein the channel has a quadrangular groove shape having the edges as a center line.

### Claim 3 (depends on 2)

The metal nanoparticle of claim 2, wherein the channel has a rectangular groove shape.

### Claim 4 (depends on 1)

The metal nanoparticle of claim 1, wherein the (100) facets with truncated edges have a quadrangular shape.

### Claim 5 (depends on 1)

The metal nanoparticle of claim 1, wherein the (111) facets with truncated edges have a triangular shape.

### Claim 6 (depends on 1)

The metal nanoparticle of claim 1, wherein a ratio of an area of the (111) facet with truncated edges to an area of the (100) facet with truncated edges is 5.3 to 6.5.

### Claim 7 (depends on 1)

The metal nanoparticle of claim 1, wherein the metal is any one selected from the group consisting of gold (Au), silver (Ag), copper (Cu), platinum (Pt), and palladium (Pd).

### Claim 8 (depends on 1)

A plasmonic biosensor comprising:
a substrate; and
a metal nanoparticle array in which a plurality of metal nanoparticles according to claim 1 are arranged on the substrate.

### Claim 9 (depends on 8)

The plasmonic biosensor of claim 8, wherein the metal nanoparticle array is configured so that the plurality of metal nanoparticles are in contact with each other.

### Claim 10 (depends on 8)

The plasmonic biosensor of claim 8, wherein a capture antibody is bound to the metal nanoparticles.

### Claim 11 (depends on 8)

The plasmonic biosensor of claim 8, further comprising a Raman probe comprising a gold nanoparticle and a detection antibody bound to the gold nanoparticle.

### Claim 12 (depends on 8)

The plasmonic biosensor of claim 8, which is used to detect a sepsis biomarker.

### Claim 13 (depends on 12)

The plasmonic biosensor of claim 12, wherein the sepsis biomarker is a myokine or an adipokine.

### Claim 14 (depends on 13)

The plasmonic biosensor of claim 13, wherein the myokine is oncostatin M or leukemia inhibitory factor (LIF).

### Claim 15 (depends on 13)

The plasmonic biosensor of claim 13, wherein the adipokine is visfatin.

### Claim 16 (depends on 8)

A method of detecting a sepsis biomarker using the plasmonic biosensor according to claim 8.
